Maturitas, 15 (1992) 265
Elsevier Scientific Publishers Ireland Ltd.

Author Index Volume 15

Alvarez del Buergo, M., 233
Ayalon, D., 25

Bachmann, G.A., 3
Backe, B., 183
Baracchini, P., 199
Berg, G., 71
Bernardini, L., 199
Boulet, M.J., 171
Byrjalsen, I., 39

Capelli, N., 225
Castelo-Branco, C., 113
Christiansen, C., 39
Clausen, H.V., 241
Coope, J., 151
Crona, N., 209

Darj, E., 209
de Cecco, L., 199
De Cooman, S., 17
de Deuxchaisnes, C.N., 17
Devogelaer, J.P., 17
di Stefano, M., 47
Drogenijk, A.C., 101
Duran, M., 113

Eckstein, N., 25
Eshel, A., 25

Feinstein, Y., 25
Felding, C., 241
Ferraiolo, A., 199
Fink, B., 61
Fioretti, P., 225
Foldes, J., 25
Fulcheri, E., 199

Gambacciani, M., 225
Garde, K., 7
Gerbaldo, D., 199
González-Merlo, J., 113

Hammer, M., 71
Hanes, V., 53
Heimer, G., 121
Hernandez, E.R., 233
Heytmanek, G., 53
Hotz, E., 195
Hunskaar, S., 183

Imthurn, B., 195
Isaia, G., 47

Jensen, L.C., 61

Keller, P.J., 195
Kopera, H., 1

La Vecchia, C., 141
Larsen, L.G., 241
Lehert, P., 171
Limor, R., 25
Lindgren, R., 71
Lindhard, A., 61
Loft, A., 241

Marsh, J., 151
Melis, G.B., 225
Metka, M., 53
Meuwissen, J.H.J., 33
Mikkelsen, A.L., 241
Molinatti, G.M., 47
Moret, E., 33
Mussetta, M., 47

Navarro-Morquecho, I., 33
Negri, E., 141
Nilsson, K., 121
Nilsson, S., 209

Obel, E.B., 61
Oddens, B.J., 171

Parazzini, F., 141
Pecchio, F., 47
Pescetto, G., 199
Pouilles, J.M., 217
Pryse-Davies, J., 71

Rekers, H., 101
Revilla, M., 233
Ribot, C., 217
Rico, H., 233
Riis, B.J., 39
Riphagen, F., 101
Risberg, B., 71

Sciolla, A., 47
Sitruk-Ware, R., 129
Solstad, K., 7
Spinetti, A., 225
Statter, M., 25
Steendahl, E., 61
Steinberg, R., 25

Taponeco, F., 225
Thormann, L., 39
Tremollieres, F., 217

Vagman, I., 25
Valkenburg, H.A., 101
van Langen, H., 33
Villa, L.F., 233
Visser, A.P., 171

Maturitas, 15 (1992) 267–269
Elsevier Scientific Publishers Ireland Ltd.

Subject Index Volume 15

Abrasio, oestrogen/progestogen therapy, curettage, menopause, vaccuum aspiration, 61
Age, oestrogens, skin, collagen, menopause, 113
Androgen decline, male climacteric, middle-aged men, climacteric, midlife crisis, climacteric myths, 7
Androgen therapy, male hypogonadism, bone mass, osteodensitometry, 17
Attitude to health, menopause, oestrogens, hormone replacement therapy, 183

Bleeding patterns, placental protein 14, hormone replacement therapy, endometrial response, 39
Bone densitometry, menopause, bone mass, bone mineral content, 233
Bone mass, male hypogonadism, osteodensitometry, androgen therapy, 17
Bone mass, menopause, bone mineral content, bone densitometry, 233
Bone metabolism, GnRH-analogue treatment, safety aspects, calcium homeostasis, 25
Bone mineral content, male hypogonadism, calcitonin, testosterone, bone tissue, 47
Bone mineral content, menopause, bone mass, bone densitometry, 233
Bone tissue, male hypogonadism, bone mineral content, calcitonin, testosterone, 47
Breast cancer, estrogens, progestins, epidemiology, 129

Calcitonin, male hypogonadism, bone mineral content, testosterone, bone tissue, 47
Calcitonin, osteoporosis, ovariectomy, prevention, 225
Calcium homeostasis, GnRH-analogue treatment, safety aspects, bone metabolism, 25
Climacteric myths, male climacteric, middle-aged men, climacteric, androgen decline, midlife crisis, 7
Climacteric, male climacteric, middle-aged men, androgen decline, midlife crisis, climacteric myths, 7
Clinical trial, hysterectomy, perimenopausal, 3
Collagen, oestrogens, skin, age, menopause, 113
Combined transdermal therapeutic systems, menopause, hormone replacement therapy, 195
Compliance, hormone replacement therapy, general practice, 151
Continuous regimen, hormone replacement therapy, oestradiol valerate, cyproterone acetate, lipid metabolism, postmenopause, 53
Curettage, oestrogen/progestogen therapy, menopause, abrasio, vaccuum aspiration, 61
Cyproterone acetate, hormone replacement therapy, continuous regimen, oestradiol valerate, lipid metabolism, postmenopause, 53

Endometrial response, placental protein 14, hormone replacement therapy, bleeding patterns, 39
Endometrium, hormonal replacement therapy, hysteroscopy, hyperplasia, 199
Endometrium, transdermal, estrogen, gestagen, hyperplasia, 71
Endometrium, vaginosonography, oestrogen replacement therapy, 33
Epidemiology, estrogens, progestins, breast cancer, 129
Estrogen, transdermal, gestagen, endometrium, hyperplasia, 71
Estrogens, progestins, breast cancer, epidemiology, 129

General practice, hormone replacement therapy, compliance, 151
Genital prolapse, oestradiol, 241
Genito-urinary tract, menopause, incontinence, 101
Gestagen, transdermal, estrogen, endometrium, hyperplasia, 71
GnRH-analogue treatment, safety aspects, bone metabolism, calcium homeostasis, 25

Hormonal replacement therapy, endometrium, hysteroscopy, hyperplasia, 199
Hormone replacement therapy, compliance, general practice, 151

Hormone replacement therapy, continuous regimen, oestradiol valerate, cyproterone acetate, lipid metabolism, postmenopause, 53
Hormone replacement therapy, menopause, combined transdermal therapeutic systems, 195
Hormone replacement therapy, menopause, oestrogens, attitude to health, 183
Hormone replacement therapy, non-hormonal treatment, tranquillizers, reported use, inter-country variation, 171
Hormone replacement therapy, placental protein 14, endometrial response, bleeding patterns, 39
Hyperplasia, endometrium, hormonal replacement therapy, hysteroscopy, 199
Hyperplasia, transdermal, estrogen, gestagen, endometrium, 71
Hysterectomy, perimenopausal, clinical trial, 3
Hysteroscopy, endometrium, hormonal replacement therapy, hyperplasia, 199

Incontinence, menopause, genito-urinary tract, 101
Inter-country variation, hormone replacement therapy, non-hormonal treatment, tranquillizers, reported use, 171

Lipid metabolism, hormone replacement therapy, continuous regimen, oestradiol valerate, cyproterone acetate, postmenopause, 53
Lipids, progesterone, postmenopausal, lipoproteins, 209
Lipoproteins, progesterone, postmenopausal, lipids, 209
Low-dose oestradiol, postmenopausal, vaginal atrophy, 121

Male climacteric, middle-aged men, climacteric, androgen decline, midlife crisis, climacteric myths, 7
Male hypogonadism, bone mass, osteodensitometry, androgen therapy, 17
Male hypogonadism, bone mineral content, calcitonin, testosterone, bone tissue, 47
Menopause, bone mass, bone mineral content, bone densitometry, 233
Menopause, hormone replacement therapy, combined transdermal therapeutic systems, 195
Menopause, incontinence, genito-urinary tract, 101
Menopause, oestrogen/progestogen therapy, curettage, abrasio, vaccuum aspiration, 61
Menopause, oestrogens, attitude to health, hormone replacement therapy, 183
Menopause, oestrogens, skin, collagen, age, 113
Menopause, risk factors, reproductive factors, 141
Middle-aged men, male climacteric, climacteric, androgen decline, midlife crisis, climacteric myths, 7
Midlife crisis, male climacteric, middle-aged men, climacteric, androgen decline, climacteric myths, 7

Non-hormonal treatment, hormone replacement therapy, tranquillizers, reported use, inter-country variation, 171

Oestradiol valerate, hormone replacement therapy, continuous regimen, cyproterone acetate, lipid metabolism, postmenopause, 53
Oestradiol, genital prolapse, 241
Oestrogen replacement therapy, vaginosonography, endometrium, 33
Oestrogen/progestogen therapy, curettage, menopause, abrasio, vaccuum aspiration, 61
Oestrogens, menopause, attitude to health, hormone replacement therapy, 183
Oestrogens, skin, collagen, age, menopause, 113
Oral hormone replacement therapy, osteoporosis, prevention, 217
Osteodensitometry, male hypogonadism, bone mass, androgen therapy, 17
Osteoporosis, ovariectomy, calcitonin, prevention, 225
Osteoporosis, prevention, oral hormone replacement therapy, 217
Ovariectomy, osteoporosis, calcitonin, prevention, 225

Perimenopausal, hysterectomy, clinical trial, 3
Placental protein 14, hormone replacement therapy, endometrial response, bleeding patterns, 39
Postmenopausal, low-dose oestradiol, vaginal atrophy, 121
Postmenopausal, progesterone, lipids, lipoproteins, 209
Postmenopause, hormone replacement therapy, continuous regimen, oestradiol valerate, cyproterone acetate, lipid metabolism, 53
Prevention, osteoporosis, oral hormone replacement therapy, 217
Prevention, osteoporosis, ovariectomy, calcitonin, 225
Progesterone, postmenopausal, lipids, lipoproteins, 209
Progestins, estrogens, breast cancer, epidemiology, 129

Reported use, hormone replacement therapy, non-hormonal treatment, tranquillizers, inter-country variation, 171
Reproductive factors, menopause, risk factors, 141
Risk factors, menopause, reproductive factors, 141

Safety aspects, GnRH-analogue treatment, bone metabolism, calcium homeostasis, 25
Skin, oestrogens, collagen, age, menopause, 113
Testosterone, male hypogonadism, bone mineral content, calcitonin, bone tissue, 47
Tranquillizers, hormone replacement therapy, non-hormonal treatment, reported use, inter-country variation, 171
Transdermal, estrogen, gestagen, endometrium, hyperplasia, 71

Vaginal atrophy, low-dose oestradiol, postmenopausal, 121
Vaginosonography, endometrium, oestrogen replacement therapy, 33